长链非编码RNA UCID通过阻止DHX9介导的CDK6下调促进G1/S期转换和肝癌生长
研究鉴定了一种致癌长链非编码RNA lnc-UCID,其在肝细胞癌中上调且高水平与患者无复发生存期缩短相关。机制上,lnc-UCID通过竞争性结合DHX9,阻止DHX9与CDK6 mRNA的3'非翻译区结合,从而上调CDK6表达,促进G1/S期转换和细胞增殖。小鼠异种移植模型中,沉默lnc-UCID的肝癌细胞形成的肿瘤体积明显小于对照,瘤内注射lnc-UCID小干扰RNA可抑制移植瘤生长。lnc-UCID基因在肝癌中频繁扩增,miR-148a下调与lnc-UCID升高相关,且miR-148a可结合并抑制lnc-UCID表达。
要点
- lnc-UCID在肝细胞癌中上调,高水平与无复发生存期缩短相关。
- lnc-UCID通过竞争性结合DHX9,阻止DHX9对CDK6的转录后抑制,上调CDK6促进G1/S期转换。
- 小鼠异种移植模型中,沉默lnc-UCID的肿瘤体积明显小于对照,瘤内注射lnc-UCID小干扰RNA可抑制移植瘤生长。
核心结论
- lnc-UCID上调可能由基因座扩增和miR-148a下调所致,通过阻止DHX9与CDK6相互作用并增强CDK6表达促进肝癌生长。
研究设计与样本
- 研究采用功能获得和功能缺失实验、小鼠异种移植模型及分子机制实验鉴定lnc-UCID在肝细胞癌中的作用。
主要发现
- lnc-UCID在肝细胞癌中上调,较高lnc-UCID水平与肝细胞癌患者较短的无复发生存期相关。
- lnc-UCID增强CDK6表达,促进G1/S期转换和细胞增殖。
- 小鼠异种移植模型中,沉默lnc-UCID的肝细胞癌细胞形成的肿瘤体积明显小于对照细胞形成的肿瘤,瘤内注射lnc-UCID小干扰RNA抑制移植瘤生长。
- lnc-UCID的850-1030核苷酸结构域与DHX9物理结合;DHX9通过结合CDK6 mRNA的3'非翻译区转录后抑制CDK6表达;lnc-UCID通过竞争性结合DHX9并使其从CDK6-3'非翻译区隔离来增强CDK6表达。
- lnc-UCID基因在肝细胞癌中频繁扩增;miR-148a下调与肝细胞癌中lnc-UCID升高相关,miR-148a可结合lnc-UCID并抑制其表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although thousands of long noncoding RNAs (lncRNAs) have been annotated, only a limited number of them have been functionally characterized. Here, we identified an oncogenic lncRNA, named lnc-UCID (lncRNA up-regulating CDK6 by interacting with DHX9). Lnc-UCID was up-regulated in hepatocellular carcinoma (HCC), and a higher lnc-UCID level was correlated with shorter recurrence-free survival of HCC patients. Both gain-of-function and loss-of function studies revealed that lnc-UCID enhanced cyclin-dependent kinase 6 (CDK6) expression and thereby promoted G1/S transition and cell proliferation. Studies from mouse xenograft models revealed that tumors derived from lnc-UCID-silenced HCC cells had a much smaller size than those from control cells, and intratumoral injection of lnc-UCID small interfering RNA suppressed xenograft growth. Mechanistically, the 850-1030-nt domain of lnc-UCID interacted physically with DEAH (Asp-Glu-Ala-His) box helicase 9 (DHX9), an RNA helicase. On the other hand, DHX9 post-transcriptionally suppressed CDK6 expression by binding to the 3'-untranslated region (3'UTR) of CDK6 mRNA. Further investigation disclosed that lnc-UCID enhanced CDK6 expression by competitively binding to DHX9 and sequestering DHX9 from CDK6-3'UTR. In an attempt to explore the mechanisms responsible for lnc-UCID up-regulation in HCC, we found that the lnc-UCID gene was frequently amplified in HCC. Furthermore, miR-148a, whose down-regulation was associated with an increase of lnc-UCID in HCC, could bind lnc-UCID and inhibit its expression. Conclusion: Up-regulation of lnc-UCID, which may result from amplification of its gene locus and down-regulation of miR-148a, can promote HCC growth by preventing the interaction of DHX9 with CDK6 and subsequently enhancing CDK6 expression. These findings provide insights into the biological functions of lncRNAs, the regulatory network of cell cycle control, and the mechanisms of HCC development, which may be exploited for anticancer therapy.
引用
- Wang YL, Liu JY, Yang JE, et al. Lnc-UCID Promotes G1/S Transition and Hepatoma Growth by Preventing DHX9-Mediated CDK6 Down-regulation. Hepatology. 2019. PMID: 30865310. doi:10.1002/hep.30613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。